The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

Boston Scientific anticipates that assisting in commercialising Siemens Healthineers’ 4D ICE catheter will pay dividends for ...

Boston Scientific (NYSE: BSX) today announced a catheter development and commercialization deal with Siemens Healthineers.

Current guidelines for the U.S. and Europe have a recommendation of class 2b, level of evidence B or C for LAAO in patients ...

With advancements in imaging, growing clinical evidence, and innovative treatment options, the left atrial appendage is a ...

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...

Marian Regional Medical Center has successfully completed its 500th Watchman procedure, a milestone in providing advanced treatment options for patients with atrial fibrillation (AFib). The Watchman ...

The Watchman left atrial appendage (LAA) closure device (Boston Scientific) is associated with low 1-year stroke rates, despite being used commercially in older, sicker patients than seen in pivotal ...

Photo via Salina Regional Health Center – Dr. David Battin, left, receives the Trailblazer Award from Dr. Rakesh ...

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

On the first day of the 2016 CardioStim sessions, I am happy to report a "positive" study on percutaneous left atrial appendage closure [1]. Notice I did not write Watchman. In Europe, the majority of ...